Hepatitis C and Kidney Transplantation

Abstract EN

Hepatitis C virus (HCV) infection is relatively common among patients with end-stage kidney disease (ESKD) on dialysis and kidney transplant recipients.

HCV infection in hemodialysis patients is associated with an increased mortality due to liver cirrhosis and hepatocellular carcinoma.

The severity of hepatitis C-related liver disease in kidney transplant candidates may predict patient and graft survival after transplant.

Liver biopsy remains the gold standard in the assessment of liver fibrosis in this setting.

Kidney transplantation, not haemodialysis, seems to be the best treatment for HCV+ve patients with ESKD.

Transplantation of kidneys from HCV+ve donors restricted to HCV+ve recipients is safe and associated with a reduction in the waiting time.

Simultaneous kidney/liver transplantation (SKL) should be considered for kidney transplant candidates with HCV-related decompensated cirrhosis.

Treatment of HCV is more complex in hemodialysis patients, whereas treatment of HCV recurrence in SLK recipients appears effective and safe.